# Postnatal corticosteroid exposure in very preterm infants: A French cohort study

Silvia Iacobelli, Käliani Allamèle-Moutama, Simon Lorrain, Béatrice Gouyon, Jean-Bernard Gouyon, Francesco Bonsante

► To cite this version:

Silvia Iacobelli, Käliani Allamèle-Moutama, Simon Lorrain, Béatrice Gouyon, Jean-Bernard Gouyon, et al. Postnatal corticosteroid exposure in very preterm infants: A French cohort study. Frontiers in Pharmacology, 2023, 14, 10.3389/fphar.2023.1170842. [https://doi.org/10.3389/fphar.2023.1170842](https://doi.org/10.3389/fphar.2023.1170842). [hal-04170334](https://wwwHAL.fr/hal-04170334)

HAL Id: hal-04170334

https://hal.univ-reunion.fr/hal-04170334

Submitted on 25 Jul 2023

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
<figure><img src="image_2.png" /></figure>

Check for updates

OPEN ACCESS

EDITED BY
Catherine M. T. Sherwin,
Wright State University, United States

REVIEWED BY
Kristi Watterberg,
University of New Mexico Health
Sciences Center, United States
Matthew Kielt,
Nationwide Children's Hospital,
United States

*CORRESPONDENCE
Silvia Iacobelli,
✉ silvia.iacobelli@chu-reunion.fr

SPECIALTY SECTION
This article was submitted to Obstetric and Pediatric Pharmacology, a section of the journal Frontiers in Pharmacology

RECEIVED 21 February 2023
ACCEPTED 27 March 2023
PUBLISHED 05 April 2023

CITATION
Iacobelli S, Allamèle-Moutama K, Lorrain S, Gouyon B, Gouyon J-B, Bonsante F and the Logipren Collaborative Working Group (2023), Postnatal corticosteroid exposure in very preterm infants: A French cohort study. *Front. Pharmacol.* 14:1170842. doi: 10.3389/fphar.2023.1170842

COPYRIGHT
© 2023 Iacobelli, Allamèle-Moutama, Lorrain, Gouyon, Gouyon, Bonsante and the Logipren Collaborative Working Group. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Postnatal corticosteroid exposure in very preterm infants: A French cohort study

Silvia Iacobelli¹,²*, Käliani Allamèle-Moutama²,
Simon Lorrain², Béatrice Gouyon², Jean-Bernard Gouyon²,
Francesco Bonsante¹,² and the Logipren Collaborative
Working Group

¹Néonatologie, Réanimation Néonatale et Pédiatrique, CHU Saint Pierre, Saint Pierre, France, ²Centre d'Etudes Périnatales de l'Océan Indien (UR 7388), Université de la Réunion, Saint Pierre, France

**Background:** Postnatal corticosteroids (PC) are widely used in very preterm infants. International reports and national multicenter trials describe a marked variability across countries and inter-sites, in the use of PC. Few information is available on therapeutic indications and prescription characteristics of PC.

**Aim:** The main objective of this study was to describe the exposure to PC in a large cohort of preterm infants born at less than 32 weeks of gestation, according to the prescription data of 41 tertiary-care NICUs in France. Secondary objectives were to describe therapeutic indications, day of life (DOL) of the first exposure, route of administration, duration, cumulative dose for each drug, and differences in exposure rates across centers.

**Methods:** We conducted a prospective observational cohort analysis from January 2017 to December 2021, in 41 French tertiary-care NICUs using the same computerized order-entry system.

**Results:** In total, 13,913 infants [birth weight 1144.8 (±365.6) g] were included. Among them, 3633 (26.1%) were exposed to PC, 21.8% by systemic and 10.1% by inhaled route. Within the study population, 1,992 infants (14.3%) received the first corticosteroid treatment in the first week of life and 1641 (11.8%) after DOL 7. The more frequent indications were prevention and/or treatment of bronchopulmonary dysplasia, and arterial hypotension. Hydrocortisone was the more often prescribed molecule. For systemic PC the first exposure occurred in mean at DOL 9.4 (±13.5), mean duration of treatment was 10.3 (±14.3) days, and the cumulative dose (expressed as the equivalent dose of hydrocortisone) was in median [IQR] 9.0 [5.5–28.8] mg/kg. For inhaled PC, the first exposure occurred in mean at DOL 34.1 (±19.7), and mean duration of treatment 28.5 (±24.4) days. The exposure rate ranged from a minimum of 5% to a maximum of 56% among centers, and significantly increased over the study period (p < 0.0001).

**Conclusion:** In this French cohort of very preterm infants, around one patient out to five was exposed to PC during hospital stay in the NICU. The exposure occurred early, starting from the first week of life. Exposure rate widely varied among centers. Pharmacoepidemiology studies are useful to increase knowledge on corticosteroid utilization patterns in preterm infants.
Introduction

Corticosteroid drugs are medications with several therapeutic
properties, including anti-inflammatory, anti-allergic,
immunosuppressive and cortisol-mimicking effects. Postnatal
corticosteroids (PC) represent one of the most common classes
of drugs administered to sick neonates, the more so in very low birth
weight (VLBW) infants. According to a recent cohort study
conducted in 30 Neonatal Intensive Care Units (NICUs) in the
US, the rate of exposure to at least one corticosteroid (among
dexamethasone, prednisolone and methylprednisolone) reached
38% in extremely low birth weight (ELBW) infants (Puia-
Dumitrescu et al., 2022). A pharmacoepidemiology report
covering 29 French NICUs showed that hydrocortisone was one
of the top five off-label (unapproved indication or posology)
medications prescribed in preterm infants born at less than
28 weeks of gestation (Gouyon et al., 2019). In these children, PC
are widely used due to their anti-inflammatory effects, for the
prevention and/or the treatment of bronchopulmonary dysplasia
(BPD) (Doyle, 2021), for earlier weaning of mechanical ventilation,
as well to facilitate extubation (Khemani et al., 2009). Corticosteroid
drugs are also prescribed in the treatment of refractory hypotension
in preterm infants, as they increase cortisol concentration and
responsiveness to circulating cathecolamines (Ibrahim et al., 2011).

Some PC may have adverse effects, including on the developing
brain. The benefit/risk ratio of PC administration may change
according to the chosen molecule, the route of administration,
and the infant day of life (DOL), gestational age (GA) and
morbidity risk. Based on the best knowledge available, some
molecules should be avoided, exposure should be minimized, and
systemic corticosteroids during the first week of life should be only
used in very preterm infants at high risk of BPD (Jarreau et al., 2010;
Doyle, 2021; Doyle et al., 2021). However, several reports describe a
marked variability across countries, and inter-sites, in the use of PC,
even after adjustment for infant characteristics (Nuytten et al., 2017;
Puia-Dumitrescu et al., 2022). In these studies, the indications for
use of corticosteroids in each infant are not available.

The main objective of this study was to describe the exposure
to PC in a large cohort of preterm infants born at less than
32 weeks of gestation, according to the prescription data of
41 tertiary-care NICUs in France. Secondary objectives were
to describe: 1) the therapeutic indications; 2) the time-point of
the first exposure; 3) the route of administration, duration and
cumulative dose for each drug; 4) the eventual differences in
exposure rates across centers.

Materials and methods

Study design and setting

This was an exploratory observational study carried out in
41 tertiary-care NICUs in France, from January 2017 to
December 2021.

Study population and inclusion criteria

All infants born at less than 32 weeks of gestation, and admitted
on their first DOL in one the 41 NICUs using the same computerized
order-entry system (CPOE), Logipren®, were eligible. As indicated
by a recent report, there are 68 NICUs in France
(Data.drees.solidarites-sante.gouv.fr, 2023), thus this study
examines 60% of French NICUs.

Data sources

The CPOE associated with a Clinical Decision Support System (Logipren®) has been described in previous studies (Gouyon et al., 2017; Gouyon et al., 2019). This CPOE allows medication prescription according to GA, postnatal age, post-conceptional age, body weight at the day of the prescription, and indication. The system provides a complete preselected drug prescription with drug dose, modality of administration, preparation modalities and warnings. The prescriber has to indicate the daily body weight, choose the drug, specify its indication, and modify or confirm the prescription after a warning. The database also provides information on drug adverse effects, which are recorded on the last day of treatment. At the time of prescription, all electronic prescriptions are prospectively and automatically stored on local computer servers. After full anonymization (deidentification) within each participating hospital, they are sent to the same data warehouse for subsequent analysis.

Outcomes

The main outcome of interest was PC exposure. Exposure was
defined as having at least one dose of any corticoid drug administered at
any time during the hospital stay. No exposure was defined if there were
no documented doses administered during that time. The PC of interest
(systemic or inhaled administration) were hydrocortisone,
betamethasone, prednisolone, methylprednisolone, prednisone,
dexamethasone, budesonide, fluticasone.

Secondary outcomes were the following: therapeutic indication; time of the first exposure, expressed as DOL of the first corticosteroid administration; duration of exposure, classified by total days of exposure; cumulative dose (mg/kg) of hydrocortisone and methylprednisolone. For systemic PC, the total cumulative corticosteroid dose was calculated as the sum of all doses of any intravenous or oral corticosteroid, expressed as the equivalent dose of hydrocortisone (mg/kg). The frequency and the type of PC side effects were analysed. Variations in exposure rates across centers were assessed.

Statistical analysis

Categorical variables were presented as numbers and
proportions. Continuous variables were presented as mean ±
<table><caption>TABLE 1 Characteristics of the study population and postnatal corticosteroid exposure rate.</caption><thead><tr><th rowspan="2"></th><th rowspan="2">Population n = 13913</th><th colspan="3">Gestational age (weeks of gestation)</th></tr><tr><th>(24-25) n = 1780</th><th>(26-27) n = 2954</th><th>(28-31) n = 9179</th></tr></thead><tbody><tr><td>Male, n (%)</td><td>7407 (53.2)</td><td>985 (55.3)</td><td>1511 (51.2)</td><td>4911 (53.5)</td></tr><tr><td>Birth weight (g), mean (±SD)</td><td>1144.8 (365.6)</td><td>708.5 (117.2)</td><td>874.7 (188.6)</td><td>1316.5 (314.1)</td></tr><tr><td>Length of stay (days), mean (±SD)</td><td>42.4 (32.0)</td><td>51.6 (45.8)</td><td>55.8 (37.0)</td><td>36.3 (24.4)</td></tr><tr><td>Mortality, n (%)</td><td>1415 (10.2)</td><td>649 (36.5)</td><td>437 (14.8)</td><td>329 (3.6)</td></tr><tr><td>PC exposure, n (%) [CI 95%]</td><td>3633 (26.1) [25.4; 26.8]</td><td>1232 (69.2) [67.1; 1.4]</td><td>1500 (50.8) [49.0; 2.6]</td><td>901 (9.8) [9.2; 10.4]</td></tr></tbody></table>

PC, postnatal corticosteroids; CI, confidence interval.

standard deviations or median and range. Normality was checked using the Shapiro-Wilk test. The 95% confidence intervals (95% CI) were calculated for the main outcome. Cochran-Armitage test for trend was applied. Bivariate comparisons were performed using χ2 test, or Student test for qualitative variables. A *p*-value below 0.05 was considered significant. Statistical analysis was conducted using SAS® software (Version 9.4, SAS Institute, North Carolina, United States).

# Results

## Population characteristics and PC exposure rate

During the study period, the CPOE database recorded 16,363 neonates born before 32 weeks of gestation. Among them, 2,450 were not eligible, as they were admitted in the NICU after DOL 1. In final, 13,913 newborn infants were retained for the analysis and represented the study population. Among them, 3,633 (26.1%) were exposed to at least one corticosteroid (Table 1). Overall, the exposure rate varied according to GA, the lower the GA, the higher the exposure rate.

Within the study population, 1,992 infants (14.3%) received the first corticosteroid treatment in the first week of life and 1,641 (11.8%) after DOL 7. The most frequent indication for PC during the first week of life was BPD prevention. The treatment of BPD was the main indication for PC after DOL 7. Hydrocortisone was the most prescribed corticosteroid drug throughout the hospital stay. These data are shown on Table 2.

The exposure rate of the study population varied from 23.6% to 28.0%, and there was a significant trend toward increased exposure rate over time (*p* < 0.0001).

There were key differences between exposed and not-exposed infants, regarding sex, GA, birth weight, length of hospitalization and mortality (data shown in Table 3).

## Other exposure variables of interest

Adverse effects were recorded for 46 (1.3%) of the exposed patients. The most frequent side effect was arterial hypertension (n = 17), followed by spontaneous gastrointestinal perforation (n = 8), hypertrophic cardiomyopathy (n = 5) and hyperglycaemia (n = 3).

Table 4 shows the postnatal age at the first systemic PC exposure, the duration of treatment for systemic PC and the total cumulative corticosteroid dose.

Table 5 details the time-point of the first administration, the duration of treatment and the total dose for the most prescribed systemic drugs, hydrocortisone and betamethasone.

Within the study population, 1,411 infants were exposed to aerosolized PC (budesonide, fluticasone, and dexamethasone). More precisely, 1,327 infants were exposed to budesonide, 298 were exposed to fluticasone, and 5 to dexamethasone. Thus, the most prescribed drug was budesonide, administered to 94% of infants exposed to inhaled corticosteroids. The main indications for inhaled PC were BPD treatment, and adjuvant for extubation (respectively 79.5% and 44.1% of exposed infants). Other exposure variables of interest in infants receiving aerosolized PC are illustrated in Table 6.

## Exposure rate across centers

The exposure rate to PNC varied from 5% to 56% across centers (Figure 1). In general, the exposure rate in each center was not correlated to the proportion of infants born between 24 and 27 weeks of gestation (data not shown). Variations in median cumulative dose of systemic PC among centers is illustrated in Figure 1.

# Discussion

This study describes the corticosteroid prescription practice over a 5-year period in a French cohort of very preterm infants. In this cohort, the exposure rate to PC was 26.1%, and more precisely 21.8% for systemic and 10.1% for inhaled administration. Exposed infants, compared with unexposed ones, had a lower birth weight, were born earlier, and were more often male, as in previous studies (Puia-Dumitrescu et al., 2022). This is likely because these variables are recognized risk factors associated with the occurrence of BPD (Ramos-Navarro et al., 2022). Actually, we found that the main indication for corticosteroid use in our cohort was BPD treatment.

To our knowledge, this is the first study investigating the real exposure rate to corticosteroids in a large longitudinal cohort of preterm infants cared for in NICUs, in France. The exposure rate found in our study population is higher than that reported in the multicenter cohort EPICE (Nuytten et al., 2017), where the overall
<table><caption>TABLE 2 Time-point exposure, route of administration, indications and corticosteroid drugs used in the study population.</caption><thead><tr><th rowspan="2"></th><th rowspan="2">Population n = 13913</th><th colspan="3">Gestational age (weeks of gestation)</th></tr><tr><th>(24-25) n = 1780</th><th>(26-27) n = 2954</th><th>(28-31) n = 9179</th></tr></thead><tbody><tr><td colspan="5"><strong>DOL at the first PC exposure</strong></td></tr><tr><td>Not exposed</td><td>10280 (73.9)</td><td>548 (30.8)</td><td>1454 (49.2)</td><td>8278 (90.2)</td></tr><tr><td>DOL 1-7</td><td>1992 (14.3)</td><td>771 (43.3)</td><td>837 (28.3)</td><td>384 (4.2)</td></tr><tr><td>DOL 8-14</td><td>333 (2.4)</td><td>133 (7.5)</td><td>140 (4.7)</td><td>60 (0.7)</td></tr><tr><td>DOL 15-21</td><td>404 (2.9)</td><td>124 (7.0)</td><td>172 (5.8)</td><td>108 (1.2)</td></tr><tr><td>DOL 22-28</td><td>470 (3.4)</td><td>129 (7.2)</td><td>186 (6.3)</td><td>155 (1.7)</td></tr><tr><td>DOL &gt;28</td><td>434 (3.1)</td><td>75 (4.2)</td><td>165 (5.6)</td><td>194 (2.1)</td></tr><tr><td colspan="5"><strong>Route of administration, n (%)</strong></td></tr><tr><td>Systemic</td><td>3029 (21.8)</td><td>1172 (65.8)</td><td>1261 (42.7)</td><td>596 (6.5)</td></tr><tr><td>Intravenous</td><td>2821 (20.3)</td><td>1121 (63.0)</td><td>1171 (39.6)</td><td>529 (5.8)</td></tr><tr><td>Oral</td><td>682 (4.9)</td><td>251 (14.1)</td><td>310 (10.5)</td><td>121 (1.3)</td></tr><tr><td>Inhaled</td><td>1411 (10.1)</td><td>414 (23.3)</td><td>567 (19.2)</td><td>430 (4.7)</td></tr><tr><td colspan="5"><strong>Therapeutic Indications (DOL 1-7), n (%)</strong></td></tr><tr><td>BPD prevention</td><td>1081 (7.7)</td><td>452 (25.4)</td><td>539 (18.2)</td><td>90 (0.9)</td></tr><tr><td>Hypotension</td><td>845 (6.1)</td><td>308 (17.3)</td><td>284 (9.6)</td><td>253 (2.8)</td></tr><tr><td>BPD treatment</td><td>35 (0.3)</td><td>7 (0.4)</td><td>15 (0.5)</td><td>13 (0.1)</td></tr><tr><td>Facilitate extubation</td><td>6 (0.0)</td><td>4 (0.2)</td><td>0 (0.0)</td><td>2 (0.0)</td></tr><tr><td>Obstructive dyspnoea</td><td>6 (0.0)</td><td>1 (0.1)</td><td>3 (0.1)</td><td>2 (0.0)</td></tr><tr><td>Other</td><td>175 (1.3)</td><td>58 (3.3)</td><td>65 (2.2)</td><td>52 (0.6)</td></tr><tr><td colspan="5"><strong>INN (DOL 1-7), n (%)</strong></td></tr><tr><td>Hydrocortisone</td><td>1950 (14.0)</td><td>763 (42.9)</td><td>822 (27.8)</td><td>362 (4.0)</td></tr><tr><td>Budesonide</td><td>42 (0.3)</td><td>8 (0.4)</td><td>17 (0.6)</td><td>17 (0.2)</td></tr><tr><td>Betamethasone</td><td>12 (0.1)</td><td>3 (0.2)</td><td>6 (0.2)</td><td>3 (0.0)</td></tr><tr><td>(Methyl-)Prednisolone</td><td>2 (0.0)</td><td>1 (0.1)</td><td>0 (0.0)</td><td>1 (0.0)</td></tr><tr><td colspan="5"><strong>Therapeutic Indications (DOL &gt; 7), n (%)</strong></td></tr><tr><td>BPD treatment</td><td>1753 (12.6)</td><td>637 (35.8)</td><td>725 (24.5)</td><td>391 (4.3)</td></tr><tr><td>BPD prevention</td><td>957 (8.4)</td><td>418 (23.5)</td><td>442 (20.5)</td><td>75 (0.8)</td></tr><tr><td>Hypotension</td><td>626 (4.5)</td><td>273 (15.3)</td><td>236 (8.0)</td><td>117 (1.3)</td></tr><tr><td>Facilitate extubation</td><td>84 (0.6)</td><td>38 (2.1)</td><td>37 (1.3)</td><td>9 (0.1)</td></tr><tr><td>Obstructive dyspnoea</td><td>62 (0.4)</td><td>20 (1.1)</td><td>18 (0.6)</td><td>24 (0.3)</td></tr><tr><td>Other</td><td>969 (7.0)</td><td>335 (18.8)</td><td>370 (12.5)</td><td>264 (2.9)</td></tr><tr><td colspan="5"><strong>INN (DOL &gt; 7), n (%)</strong></td></tr><tr><td>Hydrocortisone</td><td>1637 (11.8)</td><td>665 (37.4)</td><td>740 (25.1)</td><td>232 (2.5)</td></tr><tr><td>Budesonide</td><td>1298 (9.3)</td><td>400 (22.5)</td><td>524 (17.7)</td><td>374 (4.1)</td></tr><tr><td>Betamethasone</td><td>887 (6.4)</td><td>389 (21.9)</td><td>368 (12.5)</td><td>130 (1.4)</td></tr><tr><td>Fluticasone</td><td>298 (2.1)</td><td>86 (4.8)</td><td>121 (4.1)</td><td>91 (1.0)</td></tr><tr><td>Methylprednisolone</td><td>45 (0.3)</td><td>12 (0.7)</td><td>24 (0.8)</td><td>9 (0.1)</td></tr><tr><td>Dexamethasone</td><td>6 (0.0)</td><td>1 (0.1)</td><td>2 (0.1)</td><td>3 (0.0)</td></tr></tbody></table>

DOL, day of life; PC, postnatal corticosteroids; INN, international non-proprietary name of drugs.
<table><caption>TABLE 3 Comparison of exposed and non-exposed infants.</caption><thead><tr><th rowspan="2"></th><th colspan="2">Study population</th><th rowspan="2">p-value</th></tr><tr><th>Exposed n = 3633</th><th>Not-exposed n = 10280</th></tr></thead><tbody><tr><td>Male, n (%)</td><td>2077 (57.2)</td><td>5330 (51.8)</td><td>&lt;0.0001</td></tr><tr><td>Birth weight (g), mean (±SD)</td><td>871.0 (270.5)</td><td>1241.6 (345.3)</td><td>&lt;0.0001</td></tr><tr><td>Gestational age (weeks), mean (± SD)</td><td>26.5 (1.8)</td><td>29.0 (1.8)</td><td>&lt;0.0001</td></tr><tr><td>Length of stay (days), mean (± SD)</td><td>59.9 (40.5)</td><td>36.2 (25.7)</td><td>&lt;0.0001</td></tr><tr><td>Mortality, n (%)</td><td>794 (21.9)</td><td>621 (6.0)</td><td>&lt;0.0001</td></tr></tbody></table>

<table><caption>TABLE 4 Characteristics of systemic postnatal corticosteroid administration in exposed infants.</caption><thead><tr><th rowspan="2"></th><th rowspan="2">Exposed to systemic PNC n = 3029</th><th colspan="3">Gestational age (weeks of gestation)</th></tr><tr><th>(24-25) n = 1172</th><th>(26-27) n = 1261</th><th>(28-31) n = 596</th></tr></thead><tbody><tr><td colspan="5"><strong>First exposure, DOL</strong></td></tr><tr><td>Mean (±SD)</td><td>9.4 (13.5)</td><td>8.4 (11.6)</td><td>9.7 (13.3)</td><td>12.2 (16.8)</td></tr><tr><td>Median [p25%-p75%]</td><td>2 [1-15]</td><td>2 [1-14]</td><td>2 [1-14]</td><td>4 [2-19]</td></tr><tr><td>Min-max</td><td>1-127</td><td>1-110</td><td>1-127</td><td>1-103</td></tr><tr><td colspan="5"><strong>Duration of treatment for systemic PC, days</strong></td></tr><tr><td>Mean (±SD)</td><td>10.3 (14.3)</td><td>12.1 (16.1)</td><td>10.2 (13.0)</td><td>7.3 (12.2)</td></tr><tr><td>Median [p25%-p75%]</td><td>7 [3-11]</td><td>7 [3-14.5]</td><td>9 [3-11]</td><td>3.5 [2-8]</td></tr><tr><td>Min-max</td><td>1-190</td><td>1-176</td><td>1-190</td><td>1-132</td></tr><tr><td colspan="5"><strong>Cumulative dose of systemic PC<sup>a</sup>, mg/kg</strong></td></tr><tr><td>Mean (±SD)</td><td>23.4 (35.2)</td><td>27.2 (35.2)</td><td>22.0 (33.9)</td><td>19.1 (37.4)</td></tr><tr><td>Median [p25%-p75%]</td><td>9.0 [5.5-28.8]</td><td>12.0 [6.0-36.7]</td><td>9.0 [6.0-25.7]</td><td>8.0 [3.5-16.8]</td></tr><tr><td>Min-max</td><td>0.0-396.1</td><td>0.0-281.8</td><td>0.0-362.7</td><td>0.0-396.1</td></tr><tr><td colspan="5"><strong>Number of different INN, n (%)</strong></td></tr><tr><td>1</td><td>2575 (85.0)</td><td>949 (81.0)</td><td>1067 (84.6)</td><td>559 (93.8)</td></tr><tr><td>2</td><td>426 (14.1)</td><td>217 (18.5)</td><td>175 (13.9)</td><td>34 (5.7)</td></tr><tr><td>3</td><td>28 (0.9)</td><td>6 (0.5)</td><td>19 (1.5)</td><td>3 (0.5)</td></tr></tbody></table>

DOL, day of life; PC, postnatal corticosteroids; INN, international non-proprietary name of drugs.

exposure rate to PC was 13.9%. Three French tertiary-care NICUs had been included in that European study, and they displayed an exposure rate varying from 10% to 15%, in infants born at less than 29 weeks of gestation. In contrast to our study, the results of the EPICE cohort were based on questionnaires extracted from neonatal records, and on self-declared policies concerning PC prescription. This method may have underestimated actual administrations.

Our results showed a significant trend towards increasing the use of PC from 2017 to 2021 in French NICUs, and found that the first exposure to corticosteroids occurred more often during the first week of life. This can be explained by the results of the multicenter, national randomized controlled trial (RCT) published in 2017 by

Baud et al. (2016). This study, published after the results of the EPICE cohort, had proven the efficacy of early hydrocortisone administration in preventing BPD in ELBW infants (high to moderate quality of evidence). Moreover, subsequent systematic reviews and follow-up reports have shown favourable results in terms of survival without BPD (Shaffer et al., 2019) and mean-term neurodevelopmental outcome, following early exposure to hydrocortisone (Peltoniemi et al., 2009; Baud et al., 2017). This molecule was the most used corticosteroid drug in our cohort (18.4%). However, noteworthy is the fact that in 12.7% of cases it was used with the indication “BPD treatment.” Nevertheless, two recent RCT showed no benefit of later, higher-dose of

<footnote>aCalculated as the sum of all doses of any intravenous or oral corticosteroid, expressed as the equivalent dose of hydrocortisone.</footnote>
<table><caption>TABLE 5 Characteristics of hydrocortisone and betamethasone administration in exposed infants.</caption><thead><tr><th></th><th>Hydrocortisone n = 2565</th><th>Betamethasone n = 893</th></tr></thead><tbody><tr><td><strong>First exposure, DOL</strong></td><td></td><td></td></tr><tr><td>Mean (±SD)</td><td>6.7 (11.8)</td><td>27.9 (17.4)</td></tr><tr><td>Median [p25%-p75%]</td><td>2 [1-7]</td><td>23 [19-30]</td></tr><tr><td>Min-max</td><td>1-120</td><td>1-165</td></tr><tr><td><strong>Duration of treatment, days</strong></td><td></td><td></td></tr><tr><td>Mean (±SD)</td><td>9.1 (13.3)</td><td>8.9 (9.4)</td></tr><tr><td>Median [p25%-p75%]</td><td>6 [2-10]</td><td>6 [3-10]</td></tr><tr><td>Min-max</td><td>1-188</td><td>1-110</td></tr><tr><td><strong>Cumulative dose, mg/kg</strong></td><td></td><td></td></tr><tr><td>Mean (±SD)</td><td>14.5 (23.7)</td><td>1.3 (1.4)</td></tr><tr><td>Median [p25%-p75%]</td><td>8 [4-12.5]</td><td>0.9 [0.5-1.8]</td></tr><tr><td>Min-max</td><td>0.1-260</td><td>0.1-12.7</td></tr></tbody></table>

DOL, day of life.

<table><caption>TABLE 6 Exposure variables of interest for inhaled PC.</caption><thead><tr><th rowspan="2"></th><th rowspan="2">Exposed to inhaled PC n = 1411</th><th colspan="3">Gestational age (weeks of gestation)</th></tr><tr><th>(24-25) n = 414</th><th>(26-27) n = 567</th><th>(28-31) n = 9179</th></tr></thead><tbody><tr><td><strong>First exposure, DOL</strong></td><td></td><td></td><td></td><td></td></tr><tr><td>Mean (±SD)</td><td>34.1 (19.7)</td><td>36.9 (21.2)</td><td>34.1 (21.2)</td><td>31.2 (15.3)</td></tr><tr><td>Median [p25%-p75%]</td><td>29 [22-40]</td><td>31 [23-44]</td><td>29 [22-39]</td><td>28 [22-39]</td></tr><tr><td>Min-max</td><td>[1-184]</td><td>[1-119]</td><td>[1-184]</td><td>[1-97]</td></tr><tr><td><strong>Duration of treatment, days</strong></td><td></td><td></td><td></td><td></td></tr><tr><td>Mean (±SD)</td><td>28.5 (24.4)</td><td>35.6 (28.8)</td><td>30.1 (24.0)</td><td>19.7 (16.2)</td></tr><tr><td>Median [p25%-p75%]</td><td>22 [11-39]</td><td>28.5 [14-52]</td><td>23 [14-43]</td><td>16 [8-28]</td></tr><tr><td>Min-max</td><td>[1-161]</td><td>[1-152]</td><td>[1-161]</td><td>[1-95]</td></tr><tr><td><strong>Number of different INN, n (%)</strong></td><td></td><td></td><td></td><td></td></tr><tr><td>1</td><td>1192 (84.5)</td><td>335 (80.9)</td><td>480 (84.7)</td><td>376 (87.4)</td></tr><tr><td>2</td><td>219 (15.5)</td><td>79 (19.1)</td><td>87 (15.3)</td><td>54 (12.6)</td></tr></tbody></table>

hydrocortisone, to treat established or evolving BPD (Onland et al., 2019; Watterberg et al., 2022).

National recommendations for the use of corticosteroids in infants with VLBW were last updated in 2010 in France (Jarreau et al., 2010) (ANSM, 2010). The French Agency of Drug Safety (ANSM, 2010) discourages early betamethasone administration, and suggests not administering this molecule before the third postnatal week of life. Systemic dexamethasone is not recommended for the prevention or treatment of chronic lung disease in preterm infants. The conduct of betamethasone and dexamethasone prescriptions seems consistent with these

guidelines in our cohort. Indeed, betamethasone was used in 6.4% of the study population, and the mean time-point of the first administration was at 27.6 DOL. The first administration time of betamethasone in our study is consistent with recent findings on the association between timing of systemic PC and severity of BPD (Harmon et al., 2020; Cuna et al., 2021). Results from two retrospective cohorts of very (Cuna et al., 2021) and extremely (Harmon et al., 2020) preterm infants, showed that later treatment (after DOL 36 and DOL 50 respectively) was associated with increased likelihood to develop severe BPD, compared to earlier treatment.
<figure><img src="image_3.png" /></figure>

Our results showed an extremely low exposure to dexamethasone, as only six infants within the study population received this drug. These data are different from those of the EPICE cohort, showing exposure rates of 35.8% (Shaffer et al., 2019), and from those reported in some US studies (up to 38% in extremely preterm infants) (Puia-Dumitrescu et al., 2022). In the retrospective study of the UK Neonatal Collaborative (Yao et al., 2022), the rate of PC use for the prevention or treatment of BPD was 8% in 62,019 infants born at less than 32 weeks of gestation, thus substantially lower compared to our cohort. However, despite an overlapping between the study periods, it is difficult to compare these populations, as in the UK cohort dexamethasone was predominantly used, followed by late hydrocortisone.

In our study, the treatment durations for hydrocortisone and betamethasone were lower, compared to other works (Nuytten et al., 2017). Again, it is not possible to compare our data with previous studies with regard to cumulative doses, since we expressed the cumulative dose of systemic PC as the equivalent dose of hydrocortisone, and this information is not available from previous reports (Puia-Dumitrescu et al., 2022; Douglas et al., 2023).

The rate of adverse effects in our cohort was 1.3%. This rate is low, but it is likely that CPOE LOGIPREN® underestimate side effects, as these can be reported only on the day when the drug prescription is withdrawn. Non-etheless, adverse effects may occur several days after stopping the treatment (Doyle, 2021).

In our cohort, around 10% of infants were exposed to inhaled corticosteroids. The first exposure occurred on average after the first week of life. This practice is not consistent with the finding that no

significant benefits have emerged to date, based on available data on treatment with inhaled PC starting after DOL 7 (Onland et al., 2017; Filippone et al., 2019). The mean total duration of budesonide use was 28.5 days, thus slightly lower than in the trial of Bassler et al. (2015), studying the short-term and long-term efficacy and safety of early inhaled budesonide for the prevention of BPD in extremely preterm infants. This RCT had found higher mortality rate among neonates who received budesonide compared to placebo. This information was not available in the present study, as we did not analyse prespecified secondary outcomes associated with inhaled corticosteroids.

As expected, there was a great variability in corticosteroid exposure and in median cumulative dose of systemic PC across sites. Interestingly, we did not find a link between exposure rates and patient severity (as estimated based on the proportion of extremely preterm infants cared for in each center). This leads us to the hypothesis that administration practice of corticosteroids is still based on individual choices, and not necessarily on the patient needs. However, this interpretation cannot be confirmed by our results, as risk factor variables and clinical scores of illness were not available in this cohort. In general, we acknowledge that the present study would have benefit from the analysis of a greater number of clinical covariates and outcomes (in particular, the occurrence of BPD), which were not available in the cohort. This is one limitation of our research. Another limitation is the lack of information on prenatal corticosteroid administration, which is also a factor that positively influences the prognosis of premature infants, as it reduces the severity and the occurrence of respiratory distress, and therefore the need for PC. Our study has several strengths. Due to the high number of included sites, our cohort can be considered a nationwide
representative sample of practice in NICUs. In addition, the
strength of this study also lays on the large number of the
included infants, and on the exhaustive information available,
regarding prescriptions. Since all included units participate to a
benchmarking program of their prescriptions, data collection is
prospective, rigorous, homogeneous and corresponding to real
prescriptions. We finally note that the number of missing data is
negligible in our database.

Conclusion

This study described the corticosteroid exposure rate and
prescription practice in a French cohort of very preterm babies.
The results allow us to conclude that the use of corticosteroids
remains frequent in NICUs, as one out of every five very preterm
infants is exposed to at least one corticosteroid drug during the
hospital stay. This exposure occurs early, starting from the first week
of life. Adherence to national guidelines and practice
implementation regarding warnings on PC use are satisfying. The
increasing use of hydrocortisone in the prevention of BPD reflects
results of recent studies on this molecule. These results argue for
continuation of long-term follow-up and optimization of
corticosteroid use in vulnerable infants.

Logipren collaborative working group

S. Abasse, CH Mayotte; C. Alexandre, CHU Caen; R. Brat, CHR
Orléans; D. Brault, CH Argenteuil; L. Brisseau, CH Vannes; P. Boize,
CH Pontoise; Y. Couringa, CH Cayenne; F. Decobert, CHI Créteil;
C. Desbruyeres, CH Chambéry; M. Dorsi, CHT Nouméa; A.
Elgellab, CH Lens; G. Escourrou, CHI Montreuil, F. Flamein,
CHU Lille; O. Flechelles, CHU Martinique; G. Ghostine, CHU
Amiens; O. Girard, CH St-Denis; E. Jobard, CH Saint-Brieuc: L.
Karaoui, CH Meaux; E. Kermorvant-Duchemin, Hôpital Necker
AP-HP; A. Kieffer, CH Le Mans; F. Kieffer, CH Trousseau AP-HP;
C. Lafon, CH Arras; S. Lebouedec, CHU Angers; D. Leger, CH
Basse-Terre; I. Ligi, AP-HM Conception; M. Di Maio, CHU Nîmes;
G. Mazeiras, CH Cote-Basque; F. Michel, AP-HM Timone; D.
Mitanchez, CHU Tours; F. Mons, CHU Limoges; J. Mourdie, CH
Le Havre; A. Moussy-Durandy, CHI Poissy; C. Nicaise, AP-HM
Hôpital Nord; K. Norbert, CH Pau; A. S. Pages, CH Cotentin; D.
Ramful, CHU Nord-Réunion; H. Razafimahefa, CH Corbeil-
Essonnes; J. M. Rosenthal, CHU Guadeloupe; C. Tripon, CHU
Poitiers; M. Vidal, CH Perpignan.

References

ANSM (2010). Utilisation de la corticothérapie post-natale chez le nouveau-né prématuré dans la prévention et le traitement de la dysplasie broncho-pulmonaire: état des lieux et conduite à tenir. Available at: https://archiveansm.integra.fr/var/ansm_site/storage/original/application/d6b6ec20e8828105ecc4a01ee50ec4b5.pdf (Accessed February 20, 2023).

Bassler, D., Plavka, R., Shinwell, E. S., Hallman, M., Jarreau, P. H., Carnielli, V., et al. NEUROSIS trial group (2015). early inhaled budesonide for the prevention of bronchopulmonary dysplasia. NEJM. 373(16), 1497-1506. doi:10.1056/NEJMoa1501917

Baud, O., Maury, L., Lebail, F., Ramful, D., El Moussawi, F., Nicaise, C., et al. (2016). PREMILOC trial study group effect of early low-dose hydrocortisone on survival

Data availability statement

The raw data supporting the conclusion of this article will be
made available by the authors, without undue reservation.

Ethics statement

This study was conducted in accordance with the French law
applicable to human research (Jardé Act). The specific approval of
an ethics committee is not required for this non-interventional study
based on anonymized data of authorized collections (declaration
number CNIL: DE-2015-099, DE-2017-410), and written parental
consent is not needed.

Author contributions

SI conceptualized the study, wrote the study protocol and wrote
the paper. KA-M contributed to data collection; contributed to the
study protocol; participated to the statistical analyses and to the
interpretation of the results. SL wrote the analysis plan, oversaw the
data collection, performed data analysis and participated to the
interpretation of the results. BG substantially contributed to data
collection and to statistical analysis. J-BG participated to the
interpretation of the results. FB participated to the study
conception, critically reviewed and revised the manuscript drafts.
All authors accept responsibility for the paper as submitted. All
authors read and approved the final manuscript.

Conflict of interest

The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be
construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors
and do not necessarily represent those of their affiliated
organizations, or those of the publisher, the editors and the
reviewers. Any product that may be evaluated in this article, or
claim that may be made by its manufacturer, is not guaranteed or
endorsed by the publisher.

without bronchopulmonary dysplasia in extremely preterm infants (PREMILOC): A double-blind, placebo-controlled, multicentre, randomised trial. *Lancet*. 387 (10030), 1827–36. doi:10.1016/S0140-6736(16)00202-6

Baud, O., Trousson, C., Biran, V., Leroy, E., Mohamed, D., Alberti, C., et al. (2017). Association between early low-dose hydrocortisone therapy in extremely preterm neonates and neurodevelopmental outcomes at 2 Years of age. *JAMA* 317 (13), 1329–1337. doi:10.1001/jama.2017.2692

Cuna, A., Lagatta, J. M., Savani, R. C., Vyas-Read, S., Engle, W. A., Rose, R. S., et al. (2021). Association of time of first corticosteroid treatment with bronchopulmonary dysplasia in preterm infants. *Pulmonology* 56 (10), 3283–3292. doi:10.1002/ppul.25610
Data.drees.solidarites-sante.gouv.fr (2023). Liste des maternités de France depuis 2000. Available at: https://data.drees.solidarites-sante.gouv.fr/explore/dataset/fichier_maternites_112021/information/ (Accessed February 14, 2023).

Douglas, E., Hodgson, K. A., Olsen, J. E., Manley, B. J., Roberts, C. T., Josev, E., et al. Victorian Infant Collaborative Study Group (2023). Postnatal corticosteroids and developmental outcomes in extremely preterm or extremely low birth weight infants: The Victorian Infant Collaborative Study 2016-17 cohort. *Acta Paediatr.* doi:10.1111/apa.16696

Doyle, L. W., Cheong, J. L., Hay, S., Manley, B. J., and Halliday, H. L. (2021). Early (<7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. *Cochrane Database. Syst. Rev.* 10 (10), CD001146. doi:10.1002/14651858.CD001146.pub6

Doyle, L. W. (2021). Postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia. *Neonatology* 118 (2), 244-251. doi:10.1159/000515950

Filippone, M., Nardo, D., Bonadies, L., Salvadori, S., and Baraldi, E. (2019). Update on postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia. *Am. J. Perinatol.* 36 (S02), S58-S62. doi:10.1055/s-0039-1691802

Gouyon, B., Iacobelli, S., Saliba, E., Quantin, C., Pignolet, A., Jacqz-Aigrain, E., et al. (2017). A computer prescribing order entry-clinical decision support system designed for neonatal care: Results of the 'preselected prescription' concept at the bedside. *J. Clin. Pharm. Ther.* 42 (1), 64-68. doi:10.1111/jcpt.12474

Gouyon, B., Martin-Mons, S., Iacobelli, S., Razafimahefa, H., Kermorvant-Duchemin, E., Brat, R., et al. (2019). Characteristics of prescription in 29 Level 3 Neonatal Wards over a 2-year period (2017-2018). An inventory for future research. *PLoS One.* 14 (9), e0222667. doi:10.1371/journal.pone.0222667

Harmon, H. M., Jensen, E. A., Tan, S., Chaudhary, A. S., Slaughter, J. L., Bell, E. F., et al. (2020). Timing of postnatal steroids for bronchopulmonary dysplasia: Association with pulmonary and neurodevelopmental outcomes. *J. Perinatology.* 40 (4), 616-627. doi:10.1038/s41372-020-0594-4

Ibrahim, H., Sinha, I. P., and Subhedar, N. V. (2011). Corticosteroids for treating hypotension in preterm infants. *Cochrane Database. Syst. Rev.* 2011 (12), CD003662. doi:10.1002/14651858.CD003662.pub4

Jarreau, P. H., Fayon, M., Baud, O., Autret-Leca, E., Danan, M., de Verdelhan, A., et al. (2010). The use of postnatal corticosteroid therapy in premature infants to prevent or treat bronchopulmonary dysplasia: Current situation and recommendations. *Arch. Pediatr.* 17 (10), 1480-1487. doi:10.1016/j.arcped.2010.07.013

Khemani, R. G., Randolph, A., and Markovitz, B. (2009). Corticosteroids for the prevention and treatment of post-extubation stridor in neonates, children and adults. *Cochrane Database. Syst. Rev.* 3, CD001000. doi:10.1002/14651858.CD001000.pub3

Nuytten, A., Behal, H., Duhamel, A., Jarreau, P. H., Mazela, J., Milligan, D., et al. (2017). EPICE (effective perinatal intensive care in europe) research group evidence-based neonatal unit practices and determinants of postnatal corticosteroid-use in preterm births below 30 Weeks GA in europe. A population-based cohort study. *PLoS One.* 12(1):e0170234. doi:10.1371/journal.pone.0170234

Onland, W., Onland, W., Offringa, M., and van Kaam, A. (2017). Late (≥7 days) inhalation corticosteroids to reduce bronchopulmonary dysplasia in preterm infants. *Cochrane Database. Syst. Rev.* 8 (8), CD002311. doi:10.1002/14651858.CD002311.pub4

Onland, W., Cools, F., Kroon, A., Rademaker, K., Merkus, M. P., Dijk, P. H., et al. (2019). Effect of hydrocortisone therapy initiated 7 to 14 Days after birth on mortality or bronchopulmonary dysplasia among very preterm infants receiving mechanical ventilation: A randomized clinical trial. *JAMA* 321 (4), 354-363. doi:10.1001/jama.2018.21443

Peltoniemi, O. M., Lano, A., Puosi, R., Yliherva, A., Bonsante, F., Kari, M. A., et al. (2009). Neonatal hydrocortisone working group. trial of early neonatal hydrocortisone: Two-year follow-up. *Neonatology* 95(3), 240-247. doi:10.1159/000164150

Puia-Dumitrescu, M., Wood, T. R., Comstock, B. A., Law, J. B., German, K., Perez, K. M., et al. (2022). Preterm erythropoietin neuroprotection (PENUT) trial consortium dexamethasone, prednisolone, and methylprednisolone use and 2-year neurodevelopmental outcomes in extremely preterm infants. *JAMA. Netw. Open.* 5(3), e221947. doi:10.1001/jamanetworkopen.2022.1947

Ramos-Navarro, C., Maderuelo-Rodríguez, E., Concheiro-Guisán, A., Pérez-Tarazona, S., Rueda-Esteban, S., Sánchez-Torres, A., et al. (2022). Risk factors and bronchopulmonary dysplasia severity: Data from the Spanish bronchopulmonary dysplasia research network. *Eur. J. Pediatr.* 181 (2), 789-799. doi:10.1007/s00431-021-02428-z

Shaffer, M. L., Baud, O., Lacaze-Masmonteil, T., Peltoniemi, O. M., Bonsante, F., and Watterberg, K. L. (2019). Effect of prophylaxis for early adrenal insufficiency using low-dose hydrocortisone in very preterm infants: An individual patient data meta-analysis. *J. Pediatr.* 207, 136-142.e5. doi:10.1016/j.jpeds.2018.10.004

Watterberg, K. L., Walsh, M. C., Li, L., Chawla, S., D'Angio, C. T., Goldberg, R. N., et al. (2022). Hydrocortisone to improve survival without bronchopulmonary dysplasia. *New. Engl. J. Of. Med.* 386 (12), 1121-1131. doi:10.1056/NEJMoa2114897

Yao, S., Uthaya, S., Gale, C., Modi, N., and Battersby, C., and UK Neonatal Collaborative (UKNC) (2022). Postnatal corticosteroid use for prevention or treatment of bronchopulmonary dysplasia in england and wales 2012-2019: A retrospective population cohort study. *BMJ. Open.* 12 (11), e063835. doi:10.1136/bmjopen-2022-063835